[go: up one dir, main page]

CA2204277A1 - Combined meningitis vaccine - Google Patents

Combined meningitis vaccine

Info

Publication number
CA2204277A1
CA2204277A1 CA002204277A CA2204277A CA2204277A1 CA 2204277 A1 CA2204277 A1 CA 2204277A1 CA 002204277 A CA002204277 A CA 002204277A CA 2204277 A CA2204277 A CA 2204277A CA 2204277 A1 CA2204277 A1 CA 2204277A1
Authority
CA
Canada
Prior art keywords
vaccine
oligosaccharide conjugate
hib
meningitis
oligosaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002204277A
Other languages
French (fr)
Other versions
CA2204277C (en
Inventor
Costante Ceccarini
Paolo Costantino
Sandro D'ascenzi
Francesco Norelli
Aldo Giannozzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10763774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2204277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to CA2689871A priority Critical patent/CA2689871A1/en
Publication of CA2204277A1 publication Critical patent/CA2204277A1/en
Application granted granted Critical
Publication of CA2204277C publication Critical patent/CA2204277C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A combined vaccine comprising a Haemophilus influenzae type B (Hib) oligosaccharide conjugate and a Neisseria meningitidis serogroup C (MenC) oligosaccharide conjugate. The combination vaccine is free from interference between the antigens used. The vaccine may also include a Neisseria meningitidis serogroup B (MenB) oligosaccharide conjugate. The vaccine may be used in the prophylaxis or treatment of bacterial meningitis and allows economical, safe and expedient vaccination against the prevalent causes of meningitis.
Advantageously, carrier priming may be exploited in order to maximize response to the vaccine, for example using a diphtheria, pertussis and tetanus (DTP) vaccine. The oligosaccharides are preferably size-selected and advantageously have a degree of polymerization of 4 or more.

Claims (9)

1. A combination meningitis vaccine comprising Hib and MenC oligosaccharide conjugates.
2. A vaccine according to claim 1 further comprising a MenB oligosaccharide conjugate.
3. A vaccine according to claim 1 or claim 2 wherein the oligosaccharies are size-selected in order to exclude short-chain oligomers having a degree of polymerisation of less than 4.
4. A vaccine according to any preceding claim for use in medicine.
5. A Hib oligosaccharide conjugate and a MenC
oligosaccharide conjugate for simultaneous separate or sequential administration.
6. A Hib oligosaccharide conjugate, a MenC
oligosaccharide conjugate and a MenB oligosaccharide conjugate for simultaneous separate or sequential administration.
7. A method for the prophylaxis or treatment of meningitis comprising administering to a patient a pharmaceutically effective amount of a vaccine according to any one of claims 1 to 4.
8. A method according to claim 7 wherein the administration of the vaccine is preceded by a carrier priming step.
9. A method according to claim 8 wherein the carrier priming is achieved by administration of a DTP
vaccine.
CA002204277A 1994-11-02 1995-11-02 Combined meningitis vaccine Expired - Fee Related CA2204277C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2689871A CA2689871A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9422096A GB9422096D0 (en) 1994-11-02 1994-11-02 Combined meningitis vaccine
GB9422096.9 1994-11-02
PCT/IB1995/001006 WO1996014086A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2689871A Division CA2689871A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Publications (2)

Publication Number Publication Date
CA2204277A1 true CA2204277A1 (en) 1996-05-17
CA2204277C CA2204277C (en) 2010-02-02

Family

ID=10763774

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002204277A Expired - Fee Related CA2204277C (en) 1994-11-02 1995-11-02 Combined meningitis vaccine
CA2689871A Abandoned CA2689871A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2689871A Abandoned CA2689871A1 (en) 1994-11-02 1995-11-02 Combined meningitis vaccine

Country Status (12)

Country Link
US (1) US6251401B1 (en)
EP (3) EP1312377A3 (en)
JP (3) JP3989951B2 (en)
AT (1) ATE246936T1 (en)
CA (2) CA2204277C (en)
CY (1) CY2423B1 (en)
DE (1) DE69531501T3 (en)
DK (1) DK0789587T4 (en)
ES (1) ES2204967T5 (en)
GB (1) GB9422096D0 (en)
PT (1) PT789587E (en)
WO (1) WO1996014086A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
DK0939647T4 (en) 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis serogroup B glycoconjugate and its method of use
DE69725739T2 (en) 1996-08-27 2004-08-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville MENINGOCOCCUS B-EPITOP TRAINING MONOCLONAL ANTIBODIES AND THE USE THEREOF FOR THE PRODUCTION OF VACCINE COMPOSITIONS
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
ATE372376T1 (en) * 1997-05-28 2007-09-15 Novartis Vaccines & Diagnostic CULTURE MEDIUM WITH SOYBEAN EXTRACT AS A SOURCE OF AMINO ACIDS AND WITHOUT PROTEIN COMPLEXES OF ANIMAL ORIGIN
US20040087020A1 (en) 1997-05-28 2004-05-06 Chiron S.P.A. Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
US20070259007A1 (en) * 1999-10-19 2007-11-08 Kruzel Marian L Lactoferrin: an adjuvant for vaccines
EP2292263A3 (en) * 1999-12-02 2011-07-27 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
PT1946769E (en) * 2000-06-29 2012-06-27 Smithkline Beecham Biolog Multivalent vaccine composition with reduced dose of haemophilus influenzae type b
US7534444B2 (en) 2001-04-17 2009-05-19 Novattis Vaccines And Diagnostics, Inc. Molecular mimetics of meningococcal B epitopes which elicit functionally active antibodies
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
MXPA04011249A (en) * 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
US20030124139A1 (en) * 2002-11-20 2003-07-03 Irina Esikova Compositions and methods for stabilizing biological molecules upon lyophilization
CN102319427A (en) 2003-01-30 2012-01-18 诺华疫苗和诊断有限公司 Injectable vaccines against multiple meningococcal serogroups
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
ES2397923T3 (en) 2003-10-02 2013-03-12 Novartis Ag Liquid vaccines for multiple meningococcal serogroups
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
PT1896061T (en) 2005-06-27 2019-08-01 Glaxosmithkline Biologicals Sa Immunogenic composition
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
CN101678094B (en) * 2007-06-04 2014-08-27 诺华股份有限公司 Formulation of meningitis vaccines
ATE553774T1 (en) * 2007-10-19 2012-05-15 Novartis Ag MENINGOCOCCAL VACCINE FORMULATIONS
ES2664753T3 (en) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Immune response induction compositions
PT3246044T (en) 2010-08-23 2021-02-15 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
ES2728282T3 (en) 2010-09-10 2019-10-23 Wyeth Llc Non-lipidated variants of ORF2086 antigens from Neisseria meningitidis
KR20160022402A (en) 2012-03-09 2016-02-29 화이자 인코포레이티드 Neisseria meningitidis compositions and methods thereof
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (en) 2013-09-08 2019-11-11 Pfizer Neisseria meningitidis compositions and methods thereof.
WO2016132294A1 (en) 2015-02-19 2016-08-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
PE20191107A1 (en) 2017-01-31 2019-08-26 Pfizer COMPOSITIONS OF NEISSERIA MENINGITIDIS AND RESPECTIVE METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
IT1187753B (en) * 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
IT1262896B (en) * 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
US5628496A (en) 1995-06-07 1997-05-13 Avm, Inc. Pneumatic spring
DE69725739T2 (en) * 1996-08-27 2004-08-05 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville MENINGOCOCCUS B-EPITOP TRAINING MONOCLONAL ANTIBODIES AND THE USE THEREOF FOR THE PRODUCTION OF VACCINE COMPOSITIONS

Also Published As

Publication number Publication date
EP1312377A2 (en) 2003-05-21
DK0789587T3 (en) 2003-12-01
DK0789587T4 (en) 2008-08-04
JP2007169302A (en) 2007-07-05
EP1312377A3 (en) 2004-02-04
EP2204185A1 (en) 2010-07-07
JP3989951B2 (en) 2007-10-10
GB9422096D0 (en) 1994-12-21
ES2204967T5 (en) 2008-07-01
US6251401B1 (en) 2001-06-26
JP2011016850A (en) 2011-01-27
DE69531501D1 (en) 2003-09-18
WO1996014086A1 (en) 1996-05-17
DE69531501T3 (en) 2008-11-13
ATE246936T1 (en) 2003-08-15
CA2689871A1 (en) 1996-05-17
JP4871770B2 (en) 2012-02-08
EP0789587A1 (en) 1997-08-20
CY2423B1 (en) 2004-11-12
DE69531501T2 (en) 2004-06-24
EP0789587B2 (en) 2008-04-02
EP2204185A8 (en) 2010-10-27
JPH10509701A (en) 1998-09-22
ES2204967T3 (en) 2004-05-01
PT789587E (en) 2003-12-31
EP0789587B1 (en) 2003-08-13
CA2204277C (en) 2010-02-02

Similar Documents

Publication Publication Date Title
CA2204277A1 (en) Combined meningitis vaccine
MY114786A (en) Vaccines
JP4870895B2 (en) Vaccine composition
PL1835939T3 (en) Meningococcal conjugate vaccination
EP2289546A3 (en) Injectable vaccines against multiple meningococcal serogroups
CA2366314A1 (en) Protein d from haemophilus influenzae as a carrier protein in combination vaccines
JP2005508849A5 (en)
JP2004501873A5 (en)
RU2009134033A (en) LIQUID VACCINES FOR MULTIPLE SERIES OF MENINGOCOCCUS
CY1111814T1 (en) INCLUSION OF VACCINATION OF MINING MACHINES
NZ602682A (en) Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU3251697A (en) Multivalent dtp-polio vaccines
CA2188284A1 (en) Group a streptococcal polysaccharide immunogenic compositions and methods
EP1782836A3 (en) Hapten-carrier conjugates for use in drug-abuse therapy (cocaine)
NO974727L (en) Immunogenic and immunostimulatory oligosaccharide compositions and methods for their preparation
AU3313789A (en) Haemophilus influenza type B oxidized polysaccharide-outer membrane protein conjugate vaccine
UA27754C2 (en) Combination pediatric vaccine, method of simultaneous combined vaccination
WO2000051633A3 (en) MULTI-COMPONENT VACCINE COMPRISING AT LEAST THREE ANTIGENS TO PROTECT AGAINST DISEASE CAUSED BY $i(HAEMOPHILUS INFLUENZAE)
Anderson Immunogenic conjugates.
Devi et al. Antibodies to poly (2 arrow right 8)- alpha-acetylneuraminic acid) and poly ((2 arrow right 9)- alpha-N-acetylneuraminic acid) are elicited by immunization of mice groups B and C meningococci and E. coli K 1.
Walther et al. Therapy of infections in immunocompromised patients with imipenem/cilastatin.
NZ337730A (en) use of an oligosaccharide hapten- carrier conjugate for immunizing against a bacterial or viral pathogen by administering
NZ609888A (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
TH29518B (en) Vaccine composition containing conjugated polysaccharides, antigens adsorbed on aluminum phosphate.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141103